Theranostics
Advancing Precision Medicine Through Intelligent Biotherapy Monitoring
Theranostics is transforming the monitoring of biotherapies. As biologics become central to modern treatment strategies, precise and objective assessment of patient response is essential to optimize outcomes and maximize therapeutic value.
By going beyond traditional diagnostics, theranostics enables personalized treatment through therapeutic drug monitoring (TDM) and advanced insights. It supports early detection of reduced efficacy, identification of anti-drug antibodies, and proactive treatment adjustments.
This approach turns data into actionable insights, helping clinicians improve patient outcomes while ensuring more efficient use of high-value therapies—driving the shift toward precision medicine.
Transforming biotherapy management through the combined power of diagnostics and therapy
Theradiag, in collaboration with Biosynex, offers a comprehensive range of CE-marked TRACKER® kits designed for the monitoring of patients treated with anti-TNF alpha therapies. These high medical value assays were among the first of their kind and provide a complete solution for therapeutic drug monitoring.
Lisa-Tracker
i-Tracker
ez-Tracker
Chorus Promonitor delivers a fully automated and efficient solution for therapeutic drug monitoring, combining accuracy, flexibility, and ease of use within a single platform.
- Fast turnaround time for confident, same-day clinical decisions
- Broad dynamic range covering all relevant therapeutic decision points
- Ready-to-use single tests for maximum simplicity and minimal hands-on time
- Fully automated, random-access system with complete traceability for seamless workflow integration
Theranostics
| wdt_ID | wdt_created_by | wdt_created_at | wdt_last_edited_by | wdt_last_edited_at | PRODUCT | CATEGORY | TECHNIQUE | MORE INFO |
|---|---|---|---|---|---|---|---|---|
| 317 | bmd | 27/08/2026 10:46 AM | bmd | 27/08/2026 10:46 AM | CHORUS Promonitor® Infliximab | Chorus Promonitor | https://bmd.be/wp-content/uploads/2026/08/Flyer_Chorus_Promonitor_ENG_BMD_rev01_2025.pdf | |
| 318 | bmd | 27/08/2026 10:46 AM | bmd | 27/08/2026 10:46 AM | CHORUS Promonitor®anti-Infliximab | Chorus Promonitor | https://bmd.be/wp-content/uploads/2026/08/Flyer_Chorus_Promonitor_ENG_BMD_rev01_2025.pdf | |
| 319 | bmd | 27/08/2026 10:46 AM | bmd | 27/08/2026 10:46 AM | CHORUS Promonitor® Adalimumab | Chorus Promonitor | https://bmd.be/wp-content/uploads/2026/08/Flyer_Chorus_Promonitor_ENG_BMD_rev01_2025.pdf | |
| 320 | bmd | 27/08/2026 10:46 AM | bmd | 27/08/2026 10:46 AM | CHORUS Promonitor® anti-Adalimumab | Chorus Promonitor | https://bmd.be/wp-content/uploads/2026/08/Flyer_Chorus_Promonitor_ENG_BMD_rev01_2025.pdf | |
| 321 | bmd | 27/08/2026 10:46 AM | bmd | 27/08/2026 10:46 AM | CHORUS Promonitor® Vedolizumab | Chorus Promonitor | https://bmd.be/wp-content/uploads/2026/08/Flyer_Chorus_Promonitor_ENG_BMD_rev01_2025.pdf | |
| 322 | bmd | 27/08/2026 10:46 AM | bmd | 27/08/2026 10:46 AM | CHORUS Promonitor® anti-Vedolizumab | Chorus Promonitor | https://bmd.be/wp-content/uploads/2026/08/Flyer_Chorus_Promonitor_ENG_BMD_rev01_2025.pdf | |
| 323 | bmd | 27/08/2026 10:46 AM | bmd | 27/08/2026 10:46 AM | CHORUS Promonitor® Ustekinumab | Chorus Promonitor | https://bmd.be/wp-content/uploads/2026/08/Flyer_Chorus_Promonitor_ENG_BMD_rev01_2025.pdf | |
| 324 | bmd | 27/08/2026 10:46 AM | bmd | 27/08/2026 10:46 AM | CHORUS Promonitor® anti-Ustekinumab | Chorus Promonitor | https://bmd.be/wp-content/uploads/2026/08/Flyer_Chorus_Promonitor_ENG_BMD_rev01_2025.pdf | |
| 325 | bmd | 27/08/2026 10:46 AM | bmd | 27/08/2026 10:46 AM | CHORUS Promonitor® Etanercept | Chorus Promonitor | https://bmd.be/wp-content/uploads/2026/08/Flyer_Chorus_Promonitor_ENG_BMD_rev01_2025.pdf | |
| 326 | bmd | 27/08/2026 10:46 AM | bmd | 27/08/2026 10:46 AM | CHORUS Promonitor® anti-Etanercept | Chorus Promonitor | https://bmd.be/wp-content/uploads/2026/08/Flyer_Chorus_Promonitor_ENG_BMD_rev01_2025.pdf | |
| 327 | bmd | 27/08/2026 10:46 AM | bmd | 27/08/2026 10:46 AM | CHORUS Promonitor® Golimumab | Chorus Promonitor | https://bmd.be/wp-content/uploads/2026/08/Flyer_Chorus_Promonitor_ENG_BMD_rev01_2025.pdf | |
| 328 | bmd | 27/08/2026 10:46 AM | bmd | 27/08/2026 10:46 AM | CHORUS Promonitor® anti-Golimumab | Chorus Promonitor | https://bmd.be/wp-content/uploads/2026/08/Flyer_Chorus_Promonitor_ENG_BMD_rev01_2025.pdf | |
| 329 | bmd | 27/08/2026 10:46 AM | bmd | 27/08/2026 10:46 AM | LISA-TRACKER Duo Infliximab | Lisa Tracker | EIA, CLIA, POC | https://bmd.be/wp-content/uploads/2026/08/LISA-TRACKER-EN-11052026_BMD.pdf |
| 330 | bmd | 27/08/2026 10:46 AM | bmd | 27/08/2026 10:46 AM | LISA-TRACKER Duo Adalimumab | Lisa Tracker | EIA, CLIA, POC | https://bmd.be/wp-content/uploads/2026/08/LISA-TRACKER-EN-11052026_BMD.pdf |
| 331 | bmd | 27/08/2026 10:46 AM | bmd | 27/08/2026 10:46 AM | LISA-TRACKER Duo Bevacizumab | Lisa Tracker | EIA, CLIA | https://bmd.be/wp-content/uploads/2026/08/LISA-TRACKER-EN-11052026_BMD.pdf |
| 332 | bmd | 27/08/2026 10:46 AM | bmd | 27/08/2026 10:46 AM | LISA-TRACKER Duo Etanercept | Lisa Tracker | EIA, CLIA, POC | https://bmd.be/wp-content/uploads/2026/08/LISA-TRACKER-EN-11052026_BMD.pdf |
| 333 | bmd | 27/08/2026 10:46 AM | bmd | 27/08/2026 10:46 AM | LISA-TRACKER Duo Certolizumab Pegol | Lisa Tracker | EIA, CLIA, POC | https://bmd.be/wp-content/uploads/2026/08/LISA-TRACKER-EN-11052026_BMD.pdf |
| 334 | bmd | 27/08/2026 10:46 AM | bmd | 27/08/2026 10:46 AM | LISA-TRACKER Duo Golimumab | Lisa Tracker | EIA, CLIA, POC | https://bmd.be/wp-content/uploads/2026/08/LISA-TRACKER-EN-11052026_BMD.pdf |
| 335 | bmd | 27/08/2026 10:46 AM | bmd | 27/08/2026 10:46 AM | LISA-TRACKER Duo Rituximab | Lisa Tracker | EIA, CLIA, POC | https://bmd.be/wp-content/uploads/2026/08/LISA-TRACKER-EN-11052026_BMD.pdf |
| 336 | bmd | 27/08/2026 10:46 AM | bmd | 27/08/2026 10:46 AM | LISA-TRACKER Duo Tocilizumab | Lisa Tracker | EIA, CLIA, POC | https://bmd.be/wp-content/uploads/2026/08/LISA-TRACKER-EN-11052026_BMD.pdf |
| 337 | bmd | 27/08/2026 10:46 AM | bmd | 27/08/2026 10:46 AM | LISA-TRACKER Duo Trastuzumab | Lisa Tracker | EIA, CLIA, POC | https://bmd.be/wp-content/uploads/2026/08/LISA-TRACKER-EN-11052026_BMD.pdf |
| 338 | bmd | 27/08/2026 10:46 AM | bmd | 27/08/2026 10:46 AM | LISA-TRACKER Duo Ustekinumab | Lisa Tracker | EIA, CLIA, POC | https://bmd.be/wp-content/uploads/2026/08/LISA-TRACKER-EN-11052026_BMD.pdf |
| 339 | bmd | 27/08/2026 10:46 AM | bmd | 27/08/2026 10:46 AM | LISA-TRACKER Duo Vedolizumab | Lisa Tracker | EIA, CLIA, POC | https://bmd.be/wp-content/uploads/2026/08/LISA-TRACKER-EN-11052026_BMD.pdf |
| 340 | bmd | 27/08/2026 10:46 AM | bmd | 27/08/2026 10:46 AM | LISA-TRACKER Duo Secukinumab | Lisa Tracker | EIA, CLIA, POC | https://bmd.be/wp-content/uploads/2026/08/LISA-TRACKER-EN-11052026_BMD.pdf |
| 341 | bmd | 27/08/2026 10:46 AM | bmd | 27/08/2026 10:46 AM | LISA-TRACKER Infliximab | Lisa Tracker | EIA, CLIA, POC | https://bmd.be/wp-content/uploads/2026/08/LISA-TRACKER-EN-11052026_BMD.pdf |